Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Mitsubishi Tanabe Eyes US as 1st Launch Market, Zeroes in on Immunology/CNS: Chief
January 22, 2019
- Janssen, Nippon Shinyaku to Copromote Prostate Cancer Treatment Apalutamide in Japan
January 22, 2019
- Shionogi Facing Xofluza Supply Crunch as Flu Season Gets into Full Swing
January 21, 2019
- Meiji Gets Thailand/Indonesia Rights to Toray’s Remitch
January 21, 2019
- Opdivo Wins Label Expansion for NSCLC in Taiwan: Ono
January 21, 2019
- Eisai’s Voluntary Redundancy Program Draws 300 Applicants in 1st Round, 3 Times More than Planned
January 21, 2019
- Chugai Files Gene Panel Test for Use as Companion Diagnostic to Entrectinib
January 21, 2019
- Novo to Cease Dealings with 6 Wholesalers from April to Cut Distribution Costs
January 21, 2019
- Mitsubishi Tanabe Staffers Tapping New Support System to Balance Work and Infertility, Medical Treatment
January 18, 2019
- Ethical Drug Sales Slip 0.2% in November: Crecon
January 18, 2019
- Astellas, AstraZeneca Wind Up Symbicort Collaboration
January 18, 2019
- Takeda Becomes 1st Japan Drug Maker to Ring Opening Bell at NYSE
January 16, 2019
- Daiichi Sankyo Launches PIII DS-8201 Study in HER2-Low Breast Cancer
January 16, 2019
- Beverage Maker DyDo to Enter Orphan Drug Field Aiming at “Second Pillar of Business”
January 16, 2019
- Insomnia Treatment Lemborexant Filed for US Approval: Eisai, Purdue Pharma
January 16, 2019
- Fujifilm to Introduce Automatic Aseptic Filling System in US Bio CDMO Hub
January 16, 2019
- Mitsubishi Tanabe Stepping Up Rupafin Promotion in November: Anterio
January 15, 2019
- Japan Pharma Market Sags 2% in April-December as Pricing Overhaul Weighs: Encise
January 15, 2019
- Avastin Top-Seller Medicine in Japan in December: Encise Snapshot
January 11, 2019
- Wakamoto Kicks Off Japan PIII for Glaucoma Drug
January 11, 2019
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…